Advanced search
Publication Cover
Expert Review of Molecular Diagnostics Volume 15, 2015 - Issue 12
Submit an article Journal homepage
636
Views
32
CrossRef citations to date
0
Altmetric
Reviews

Transcriptomics in cancer diagnostics: developments in technology, clinical research and commercialization

Monica SagerCollege of Arts and Sciences, Washington University in St. Louis, St. Louis, MO, USA;Rare Genomics Institute, Bethesda, MD, USA
,
Nai Chien YeatRare Genomics Institute, Bethesda, MD, USA;School of Medicine, Washington University in St. Louis, St. Louis, MO, USA
,
Stefan Pajaro-Van der StadtCollege of Arts and Sciences, Washington University in St. Louis, St. Louis, MO, USA;Rare Genomics Institute, Bethesda, MD, USA
,
Charlotte LinRare Genomics Institute, Bethesda, MD, USA;School of Medicine, Washington University in St. Louis, St. Louis, MO, USA
,
Qiuyin RenRare Genomics Institute, Bethesda, MD, USA;Whiting School of Engineering, Johns Hopkins University, Baltimore, MD, USA
&
Jimmy LinRare Genomics Institute, Bethesda, MD, USACorrespondence[email protected]
Pages 1589-1603 | Published online: 13 Nov 2015

References

  • Papers of special note have been highlighted as:
  • * of interest
  • ** of considerable interest
  • Elsheikh TM, Asa SL, Chan JK, et al. Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma. Am J Clin Pathol. 2008;130(5):736–744.
  • Jordan B. Historical background and anticipated developments. Ann N Y Acad Sci. 2002;975:24–32.
  • Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937–1947.
  • Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–511.

** A report exploring gene expression patterns in diffuse large B-cell lymphoma (DLBCL) to further categorize the disease.

  • Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747– 752.
  • Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98(19):10869–10874.
  • Ross DT, Scherf U, Eisen MB, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet. 2000;24(3):227–235.
  • Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105(30):10513–10518.
  • Morimura R, Komatsu S, Ichikawa D, et al. Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. Br J Cancer. 2011;105(11):1733–1740.
  • Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002;99(24):15524–15529.
  • Croce C. Introduction to the role of microRNAs in cancer diagnosis, prognosis, and treatment. Cancer J. 2012;18(3):213–214.
  • Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834–838.
  • Cheetham SW, Gruhl F, Mattick JS, et al. Long noncoding RNAs and the genetics of cancer. Br J Cancer. 2013;108(12):2419–2425.
  • Zovoilis A, Mungall AJ, Moore R, et al. The expression level of small non-coding RNAs derived from the first exon of protein-coding genes is predictive of cancer status. EMBO Rep. 2014;15(4):402–410.
  • Shendure J. The beginning of the end for microarrays? Nat Methods. 2008;5(7):585–587.
  • Velculescu VE, Zhang L, Vogelstein B, et al. Serial analysis of gene expression. Science. 1995;270(5235):484–487.
  • McGettigan PA. Transcriptomics in the RNA-seq era. Curr Opin Chem Biol. 2013;17(1):4–11.
  • Matsumura H, Yoshida K, Luo S, et al. High-throughput SuperSAGE for digital gene expression analysis of multiple samples using next generation sequencing. Plos One. 2010;5(8):e12010.
  • Mortazavi A, Williams BA, McCue K, et al. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods. 2008;5(7):621–628.
  • Git A, Dvinge H, Salmon-Divon M, et al. Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. RNA. 2010;16(5):991–1006.
  • Baker M. Digital PCR hits its stride. Nat Methods. 2012;9:541–544.
  • Perkel JM. Life science technologies: The digital PCR revolution. Science. 2014;344(6180):212–214. doi:10.1126/science.344.6180.212
  • Zhao S, Fung-Leung WP, Bittner A, et al. Comparison of RNA-Seq and microarray in transcriptome profiling of activated T cells. Plos One. 2014;9(1):e78644.

** A detailed review of RNA-Seq technology compared to microarray technology for transcriptome profilling.

  • Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet. 2009;10(1):57–63.
  • Peng Z, Cheng Y, Tan BC-M, et al. Comprehensive analysis of RNA-Seq data reveals extensive RNA editing in a human transcriptome. Nat Biotechnol. 2012;30:253–260.
  • Malone JH, Oliver B. Microarrays, deep sequencing and the true measure of the transcriptome. BMC Biol. 2011;9:34.
  • Agarwal A, Koppstein D, Rozowsky J, et al. Comparison and calibration of transcriptome data from RNA-Seq and tiling arrays. BMC Genomics. 2010;11:383.
  • Zhao W, He X, Hoadley KA, et al. Comparison of RNA-Seq by poly (A) capture, ribosomal RNA depletion, and DNA microarray for expression profiling. BMC Genomics. 2014;15(1):419.
  • Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15–21.
  • Guo Y, Sheng Q, Li J, et al. Large scale comparison of gene expression levels by microarrays and RNAseq using TCGA data. Plos One. 2013;8(8):e71462.
  • Wu AR, Neff NF, Kalisky T, et al. Quantitative assessment of single-cell RNA-sequencing methods. Nat Meth. 2014;11(1):41–46.
  • Wilkerson MD, Cabanski CR, Sun W, et al. Integrated RNA and DNA sequencing improves mutation detection in low purity tumors. Nucleic Acids Res. 2014;42(13):e107.
  • Ke R, Mignardi M, Pacureanu A, et al. In situ sequencing for RNA analysis in preserved tissue and cells. Nat Methods. 2013;10(9):857–860.
  • Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352(25):2589–2597.
  • Shao W, Wang D, He J. The role of gene expression profiling in early-stage non-small cell lung cancer. J Thorac Dis. 2010;2(2):89–99.

** A detailed review focused on the role of gene expression profiling in lung cancer as a predictive and prognostic biomarker.

  • Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55–65.
  • Drukker CA, Bueno-de-Mesquita JM, Retel VP, et al. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer. 2013;133(4):929–936.
  • Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008;26(3):317–325.
  • Stahlberg A, Kubista M. The workflow of single-cell expression profiling using quantitative real-time PCR. Expert Rev Mol Diagn. 2014;14(3):323–331.

**A review of the current state of the art of single-cell expression profiling.

  • Vriens MR, Weng J, Suh I, et al. MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer. Cancer. 2012;118(13):3426–3432.
  • Monroig PD, Calin GA. MicroRNA and epigenetics: diagnostic and therapeutic opportunities. Curr Pathobiol Rep. 2013;1(1):43–52.
  • Sun L, Xu J. Feature selection using mutual information based uncertainty measures for tumor classification. Biomed Mater Eng. 2014;24(1):763–770.

** A tumor classification approach with neighborhood rough set-based feature selection.

  • Ding C, Peng H. Minimum redundancy feature selection from microarray gene expression data. J Bioinform Comput Biol. 2005;3(2):185–205.
  • Goodison S, Sun Y, Urquidi V. Derivation of cancer diagnostic and prognostic signatures from gene expression data. Bioanalysis. 2010;2(5):855–862.
  • Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11(16):5678–5685.
  • Harbeck N, Sotlar K, Wuerstlein R, et al. Molecular and protein markers for clinical decision making in breast cancer: today and tomorrow. Cancer Treat Rev. 2014;40(3):434–444.

*A review summarizing the methodology, analytical and clinical validation of various prognosis/predictive tests for early breast cancer.

  • Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726–3734.
  • Solin LJ, Gray R, Baehner FL, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013;105(10):701–710.
  • Holt S, Bertelli G, Humphreys I, et al. A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the U.K. Br J Cancer. 2013;108(11):2250–2258.
  • Mulcahy N. It’s Oncotype DX vs MammaPrint in Europe [Internet]. Medscape; 2014. [cited 2014 May 8]. Available from: http://www.medscape.com/viewarticle/824874
  • Wang H, Molina J, Jiang J, et al. Gene expression markers in circulating tumor cells may predict bone metastasis and response to hormonal treatment in breast cancer. Mol Clin Oncol. 2013;1(6):1031–1038.

*A study identifying potential biomarkers for metastatic breast cancer.

  • Andres SA, Brock GN, Wittliff JL. Interrogating differences in expression of targeted gene sets to predict breast cancer outcome. BMC Cancer. 2013;13:326.
  • Glinsky GV. “Stemness” genomics law governs clinical behavior of human cancer: implications for decision making in disease management. J Clin Oncol. 2008;26(17):2846–2853.
  • Toffalorio F, Belloni E, Barberis M, et al. Gene expression profiling reveals GC and CEACAM1 as new tools in the diagnosis of lung carcinoids. Br J Cancer. 2014;110(5):1244–1249.

*A comparison of the gene expression profile of typical and atypical lung carcinoids to find diagnostic markers.

  • Altorki N, Guarino M, Lee P, et al. Preoperative treatment with pazopanib (GW786034), a multikinase angiogenesis inhibitor in early-stage non-small cell lung cancer (NSCLC): a proof-of-concept phase II study. J Clin Oncol 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition) [Internet]. [cited 2008 May 20]. 2008;26(15S):7557. Available from: http://meeting.ascopubs.org/cgi/content/short/26/15_suppl/7557
  • Altorki N, Lane ME, Bauer T, et al. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. J Clin Oncol. 2010;28(19):3131–3137.
  • Wistuba II, Behrens C, Lombardi F, et al. Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma. Clin Cancer Res. 2013;19(22):6261–6271.
  • Wilkerson MD, Schallheim JM, Hayes DN, et al. Prediction of lung cancer histological types by RT-qPCR gene expression in FFPE specimens. J Mol Diagn. 2013;15(4):485–497.
  • Schetter AJ, Okayama H, Harris CC. The role of microRNAs in colorectal cancer. Cancer J. 2012;18(3):244–252.
  • Christensen LL, Holm A, Rantala J, et al. Functional screening identifies miRNAs influencing apoptosis and proliferation in colorectal cancer. Plos One. 2014;9(6):e96767.
  • Qiu Y, Cai G, Zhou B, et al. A distinct metabolic signature of human colorectal cancer with prognostic potential. Clin Cancer Res. 2014;20(8):2136–2146.
  • Yothers G, O’Connell MJ, Lee M, et al. Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. J Clin Oncol. 2013;31(36):4512–4519.

*A review of the 12-gene Recurrence Score assay for colon cancer patients.

  • Johnston PG. Identification of clinically relevant molecular subtypes in colorectal cancer: the dawning of a new era. Oncologist. 2014;19(5):568–573.
  • Maak M, Simon I, Nitsche U, et al. Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer. Ann Surg. 2013;257(6):1053–1058.
  • Kopetz S, Freitas D, Calabrich AF, et al. Adjuvant chemotherapy for stage II colon cancer. Oncology. 2008;22(3):260–270. discussion 270, 273, 275.
  • Sveen A, Nesbakken A, Agesen TH, et al. Anticipating the clinical use of prognostic gene expression-based tests for colon cancer stage II and III: is Godot finally arriving? Clin Cancer Res. 2013;19(24):6669–6677.
  • Cheng J, Wu Y, Mohler JL, et al. The transcriptomics of de novo androgen biosynthesis in prostate cancer cells following androgen reduction. Cancer Biol Ther. 2010;9(12):1033–1042.
  • Spans L, Helsen C, Clinckemalie L, et al. Comparative genomic and transcriptomic analyses of LNCaP and C4-2B prostate cancer cell lines. Plos One. 2014;9(2):e90002.
  • Klein EA, Cooperberg MR, Magi-Galluzzi C, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol. 2014;66(3):550–560. doi:10.1016/j.eururo.2014.05.004
  • Welty CJ, Coleman I, Coleman R, et al. Single cell transcriptomic analysis of prostate cancer cells. BMC Mol Biol. 2013;14:6.

*An analysis of whether a transcriptomic profile can be reliably obtained from a single cell using commercially available technology.

  • Ren S, Peng Z, Mao JH, et al. RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings. Cell Res. 2012;22(5):806–821.
  • Knezevic D, Goddard AD, Natraj N, et al. Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics. 2013;14:690.

*A report validating the analytical performance of the Oncotype DX Prostate Cancer Assay using predefined acceptance criteria.

**An article arguing that the molecular diagnostics industry would benefit from increased FDA regulation.

** A report evaluating the cost effectiveness of recurrence score-guided treatment using 2 commercially available GEP tests, Oncotype DX and MammaPrint.

  • Reed SD, Lyman GH. Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model. Cancer. 2012;118(24):6298–6299. author reply 6299-6300.
  • Sabatier R, Goncalves A, Bertucci F. Personalized medicine: present and future of breast cancer management. Crit Rev Oncol Hematol. 2014;91(3):223–233.
  • Dubsky P, Filipits M, Jakesz R, et al. EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol. 2013;24(3):640–647.
  • Baker M. Big biology: the ‘omes puzzle. Nature. 2013;494(7438):416–419.

*An article evaluating the boom of “-omics” fields of study.

  • Kosmides AK, Kamisoglu K, Calvano SE, et al. Metabolomic fingerprinting: challenges and opportunities. Crit Rev Biomed Eng. 2013;41(3):205–221.
  • Cook-Deegan R. Are human genes patentable? Ann Intern Med. 2013;159(4):298–299.
  • Sherkow JS, Scott C. Myriad stands alone. Nat Biotechnol. 2014;32(7):620.
  • Marzinke MA, Clarke W. Laboratory developed tests in the clinical laboratory: challenges for implementation. Bioanalysis. 2015;7(15):1817–1820. doi:10.4155/bio.15.109
  • Ramaswamy S, Tamayo P, Rifkin R, et al. Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci USA. 2001;98(26):15149–15154.

*This report discusses the feasibility of accurate, multiclass molecular cancer classification with suggestions for future clinical implementation of molecular cancer diagnostics.

  • Gonzalez de Castro D, Clarke PA, Al-Lazikani B, et al. Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clin Pharmacol Ther. 2013;93(3):252–259.
  • Kalia M. Personalized oncology: recent advances and future challenges. Metabolism. 2013;62(Suppl 1):S11–14.
  • Cross D, Burmester JK. The promise of molecular profiling for cancer identification and treatment. Clin Med Res. 2004;2(3):147–150.
  • Ansari M. The regulation of companion diagnostics: a global perspective. Ther Innovation Regul Sci. 2013;47(4):405–415.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.